drugset / Trial / NCT05005312

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

NCT05005312

Phase 1 Completed 17 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of hepatic impairment.

Timeline

Start
2021-08-31
Primary completion
2021-12-07
Completion
2021-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nirmatrelvir Small molecule
Background Ritonavir Other / unclassified

Indications

No indication recorded.